Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | FGF1 | P05230 | 1/20 | 0.33 |
| ▸ | FGF2 | P09038 | 1/20 | 0.33 |
| ▸ | HK2 | P52789 | 5/20 | 0.32 |
| ▸ | HK1 | P19367 | 4/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 3/20 | 0.30 |
| ▸ | CA1 | P00915 | 3/20 | 0.30 |
| ▸ | CA9 | Q16790 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13286928 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL21067663 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL7209918 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL20987120 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL1009127 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL16728926 | 1.00 | F10 (0.42) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL15449484 | 0.87 | F10 (0.36) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL29535532 | 0.85 | F10 (0.48) | F10F2SERPINC1FGF1FGF2 | |
| SCHEMBL29534894 | 0.85 | F10 (0.43) | F10AMDHD2F2SERPINC1CA2 | |
| SCHEMBL17340086 | 0.82 | F10 (0.57) | F10SERPINC1CA2FGF1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122012440-A | Heparin 3-O-sulfate transferase mutant with high enzyme activity and high thermal stability, and encoding gene and application thereof | 山东大学 | 2026-05-12 | — | — | CN | claimed |
| US-12569512-B2 | Heparan sulfate (HS) oligosaccharides effect in liver ischemia reperfusion injury | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-03-10 | — | — | US | claimed |
| WO-2025245431-A1 | PREPARATION OF MEDIUM MOLECULAR WEIGHT HEPARIN | GLYCOS BIOMEDICAL LTD (GB) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245445-A1 | FUNCTIONALISED MEDIUM MOLECULAR WEIGHT HEPARIN | GLYCOS BIOMEDICAL LTD (GB) | 2025-11-27 | — | — | WO | claimed |
| EP-3672603-B1 | COMBINATION OF A MAPK/ERK PATHWAY INHIBITOR AND A GLYCOSAMINOGLYCAN FOR THE TREATMENT OF CANCER | Cell Receptor AG (CH) | 2025-09-24 | — | — | EP | claimed |
| EP-4619446-A1 | PREPARATION OF MEDIUM MOLECULAR WEIGHT HEPARIN | Glycos Biomedical Ltd (GB) | 2025-09-24 | — | — | EP | claimed |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG UNIVERSITY (CN) | 2025-06-12 | — | — | US | claimed |
| WO-2025106117-A1 | MEDIUM MOLECULAR WEIGHT HEPARIN | Glycos Biomedical Ltd. (GB) | 2025-05-22 | — | — | WO | claimed |
| CN-119375384-A | Method for in-vitro detection of mucopolysaccharide and pompe disease related biomarker | 浙江博圣生物技术股份有限公司 | 2025-01-28 | — | — | CN | claimed |
| US-20250019465-A1 | COMPOSITIONS AND METHODS FOR RARE HEPARAN SULFATE GLYCAN-TARGETED CANCER TREATMENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-16 | — | — | US | claimed |
| US-11559544-B2 | Combination of a MAPK/ERK pathway inhibitor and a glycosaminoglycan for the treatment of cancer | Cell Receptor AG (CH) | 2023-01-24 | — | — | US | claimed |
| WO-2023280235-A1 | HEPARIN MOLECULE CONTAINING AT BINDING SEQUENCE AND CONTINUOUS 2-O-GLUCURONIC ACID RESIDUE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东大学 | 2023-01-12 | — | — | WO | claimed |
| US-20220404379-A1 | SEQUENCING METHOD, SYSTEM AND KIT OF LOW MOLECULAR WEIGHT HEPARIN OLIGOSACCHARIDES | SHANDONG UNIVERSITY (CN) | 2022-12-22 | — | — | US | claimed |
| CN-115448994-A | Neutralization anticoagulant low molecular weight heparin and preparation method and application thereof | 山东大学 | 2022-12-09 | — | — | CN | claimed |
| CN-115417937-A | Heparin decabiose containing double-antithrombin binding sequence and preparation method and application thereof | 山东大学 | 2022-12-02 | — | — | CN | claimed |
| WO-2022238587-A1 | MEDIUM MOLECULAR WEIGHT HEPARIN FOR USE IN THE TREATMENT OF ENDOTHELIOPATHY | BHOGAL PERVINDER SINGH (GB) | 2022-11-17 | — | — | WO | claimed |
| CN-113393904-B | Method and system for detecting low-molecular heparin sugar chain sequence and sequencing kit | 山东大学 | 2022-10-18 | — | — | CN | claimed |
| CN-111154819-B | Non-animal source low molecular weight heparin and preparation method and application thereof | 山东大学 | 2022-08-30 | — | — | CN | claimed |
| CN-114264741-B | Method for identifying whether pig-derived heparin is doped with ruminant heparin | 山东大学 | 2022-08-19 | — | — | CN | claimed |
| CN-114264741-A | Method for identifying whether pig-derived heparin is doped with ruminant heparin | 山东大学 | 2022-04-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569512-B2 | Heparan sulfate (HS) oligosaccharides effect in liver ischemia reperfusion injury | HPSE, GYS2, IRS1 | F10 3709/4885AMDHD2 124/4885F2 2432/4885 |
| US-20250188506-A1 | ANTICOAGULANT HEPARIN-CHONDROITIN CHIMERIC SACCHARIDE MOLECULE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | HPSE, CD44, CSGALNACT1 | F10 46/4885AMDHD2 338/4885F2 54/4885 |
| US-20250019465-A1 | COMPOSITIONS AND METHODS FOR RARE HEPARAN SULFATE GLYCAN-TARGETED CANCER TREATMENT | HPSE, SDC4, SDC2 | F10 2318/4885AMDHD2 90/4885F2 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.